European Study Provides More Evidence Supporting IceCure's ProSense® is Safe & Effective Cryoablation Treatment for Metastatic and Recurrent Breast Cancer

Core Insights - The independent study published in the journal Cancers demonstrates that IceCure Medical's ProSense® cryoablation system is a safe and effective local treatment for breast cancer, particularly in a higher-risk patient population with metastatic disease and larger tumors [4][11][14] - The study reported an 8.9% recurrence rate among 45 patients, all of whom had previously undergone various therapies, indicating the efficacy of ProSense® in managing more complex cases of breast cancer [4][11] - The results support the broader application of ProSense® across different stages of breast cancer, from early-stage to metastatic and recurrent disease, enhancing its value proposition in the market [8][11] Company Overview - IceCure Medical (Nasdaq: ICCM) specializes in developing and marketing advanced liquid-nitrogen-based cryoablation therapy, providing a minimally invasive alternative to surgical tumor removal [2][12] - The ProSense® system is designed to create large lethal zones for effective tumor destruction, applicable to various cancers including breast, kidney, lung, and liver [9][12] - The company emphasizes the advantages of its technology, including reduced recovery time, lower pain levels, and minimized surgical risks, making it suitable for outpatient procedures [15]